BenzingaAugust 14, 2026 at 1:05 PM NY2 Months Ago
Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
